Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Table 8 Summary of costs and benefits

AE: adverse event; BSC: best supportive care; QALY: quality-adjusted life year; LYG: life year gained
Table 8 summarises costs and benefits in terms of QALYs and LYG for both pemetrexed and docetaxel. The incremental difference between both treatment arms is also presented.

ISSN: 1471-2407